Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

UFS gets support for improving university access and success in South Africa
2013-10-24

 

Members of the SASSE Research team are from left: Carike Jordaan, Dr Francois Strydom, Lana Swart, Seisho Gaboutlwelweboutlwelwakemo, Michael Henn en Katleho Nyaile.
Photo: Supplied
24 October 2013

The university’s Centre of Teaching and Learning (CTL) received a grant for US$820 000 (about R8 million) from the Kresge Foundation for their South African Survey of Student Engagement (SASSE) research team.

The SASSE research team is committed to furthering student access with success by promoting quality teaching and learning institutionally and promoting collective impact around student success nationally.

Through this three-year project, the SASSE team aims to provide a range of deeply contextualised and globally benchmarked student engagement measures that can be used at institutional and module/course level for the South African context. The data from these measures can be used to improve the quality of undergraduate teaching and learning, and participating institutions will have access to appropriate capacity development interventions to empower them to use the data to promote evidence-based change in their institutions.

Dr Francois Strydom, Academic Director at the CTL, says the lessons from this higher-education project could be used to develop a stronger post-school sector which could help the country to deal with the massive challenge of youth unemployment; thereby promoting equity, social justice and a prosperous democracy in South Africa.

The Kresge Foundation is a private philanthropic foundation in the United States, which is focused on creating opportunity for low-income people through various programmes. This three-year project forms part of the Kresge Foundation’s Education Programme, which focuses on promoting access and success at South African universities. Therefore the SASSE project aims to contribute to the Kresge-sponsored Access and Success in Higher Education in South Africa (ASHESA), to promote a national conversation on improving student success.

In January this year, the university was one of four South African universities selected to take part in a multi-million rand programme to bolster private fund-raising and advancement efforts. For this programme the UFS was granted US$640 000 (about R5,6 million) over a period of five years.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept